These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8391547)

  • 1. Cytomegalovirus pneumonitis and bone marrow transplantation: identification of a specific high risk group.
    Foot AB; Caul EO; Roome AP; Darville JM; Oakhill A
    J Clin Pathol; 1993 May; 46(5):415-9. PubMed ID: 8391547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
    Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
    Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difference in onset between cytomegalovirus and idiopathic interstitial pneumonitis following allogeneic bone marrow transplantation for leukemia.
    Inoue T; Masaoka T; Shibata H
    Strahlenther Onkol; 1990 May; 166(5):322-5. PubMed ID: 2161566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients.
    Ljungman P; Aschan J; Lewensohn-Fuchs I; Carlens S; Larsson K; Lönnqvist B; Mattsson J; Sparrelid E; Winiarski J; Ringdén O
    Transplantation; 1998 Nov; 66(10):1330-4. PubMed ID: 9846518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections.
    Grob JP; Grundy JE; Prentice HG; Griffiths PD; Hoffbrand AV; Hughes MD; Tate T; Wimperis JZ; Brenner MK
    Lancet; 1987 Apr; 1(8536):774-6. PubMed ID: 2882184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products.
    Rubie H; Attal M; Campardou AM; Gayet-Mengelle C; Payen C; Sanguignol F; Calot JP; Charlet JP; Robert A; Huguet F
    Bone Marrow Transplant; 1993 Mar; 11(3):209-14. PubMed ID: 8385522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ; Ho WG; Bartoni K; Champlin RE
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective analysis interstitial pneumonia and opportunistic viral infection among recipients of allogeneic bone marrow grafts.
    Neiman PE; Reeves W; Ray G; Flournoy N; Lerner KG; Sale GE; Thomas ED
    J Infect Dis; 1977 Dec; 136(6):754-67. PubMed ID: 21931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus infections after allogeneic bone marrow transplantation.
    Winston DJ; Ho WG; Champlin RE
    Rev Infect Dis; 1990; 12 Suppl 7():S776-92. PubMed ID: 2173107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation.
    Zekri AR; Mohamed WS; Samra MA; Sherif GM; El-Shehaby AM; El-Sayed MH
    Transpl Immunol; 2004 Dec; 13(4):305-11. PubMed ID: 15589744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection.
    Atkinson K; Downs K; Golenia M; Biggs J; Marshall G; Dodds A; Concannon A
    Br J Haematol; 1991 Sep; 79(1):57-62. PubMed ID: 1654994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
    Narvios AB; Lichtiger B
    Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytomegalovirus hyperimmune globulin prophylaxis in bone marrow transplants in children with various diseases].
    Ebell W; Blütters-Sawatzki R; Friedrich W; Hampl W; Kleihauer E
    Immun Infekt; 1985 Nov; 13(6):307-12. PubMed ID: 3000925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
    von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
    Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus antibody avidity in allogeneic bone marrow recipients: evidence for primary or secondary humoral responses depending on donor immune status.
    Lutz E; Ward KN; Szydlo R; Goldman JM
    J Med Virol; 1996 May; 49(1):61-5. PubMed ID: 8732861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors.
    De Witte T; Schattenberg A; Van Dijk BA; Galama J; Olthuis H; Van der Meer JW; Kunst VA
    Transplantation; 1990 Dec; 50(6):964-8. PubMed ID: 2175059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allogeneic bone marrow transplants.
    Humar A; Wood S; Lipton J; Messner H; Meharchand J; McGeer A; MacDonald K; Mazzulli T
    Clin Infect Dis; 1998 Mar; 26(3):606-10. PubMed ID: 9524831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus infection in recipients of related and unrelated donor bone marrow transplants: no evidence of increased incidence in patients receiving unrelated donor grafts.
    Foot AB; Pamphilon D; Caul EO; Roome AP; Hunt LP; Cornish JM; Oakhill A
    Br J Haematol; 1998 Aug; 102(3):671-7. PubMed ID: 9722292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
    Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
    Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection. An analysis of risk factors.
    Paulin T; Ringdén O; Lönnqvist B; Wahren B; Nilsson B
    Scand J Infect Dis; 1986; 18(3):199-209. PubMed ID: 3016884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.